The below article was originally written by Forbes...
On Thursday, January 19th, 2017, the city of Everett WA, filed a state lawsuit against drug maker Purdue Pharma with allegations the drug manufacturer was and continue to be a major contributing factor to opioid addiction and resultant community expenses and impact.
Everett city officials initiating the lawsuit on behalf of their constituents, seek to hold Purdue Pharma accountable for failing to take proactive steps in preventing OxyContin from entering the black market as an addictive drug that is commonly referenced as a major source of growing Opioid addictions across the United States.
The lawsuit alleges that as a result of Purdue Pharma being negligent in failing to properly institute effective controls on OxyContin, the drug was inadvertently distributed from Purdue to drug dealers, pill mills, and narcotic rings. As a result, the city of Everett has incurred substantial financial expense relating to treatment and medical care associated with OxyContin drug addiction victims.
Everett city officials contend that OxyContin addiction in their jurisdiction has a social impact on the community and costs taxpayers at nearly every department of local government, specifically via increase costs for treatment programs, police, incarcerations, and other city services.
In response, Purdue Pharma claims to have taken steps to prevent and address Oxycontin addiction which makes up 2% of all opioid prescriptions. In declaring Purdue Pharma an industry leader in opioid abuse prevention, Purdue acknowledged that it shares the nationwide concern over opioid addiction and abuse with city officials.
Regardless, the mayor of Everett was indifferent to Purdue Pharma excuses and stated “We are going to go at them, and we are going to go at them hard”
How hard, is yet to be seen as many legal experts consider the styling of this lawsuit to be a longshot.
If successful in obtaining damages from the drug maker, the city of Evertt will lay the groundwork for future litigation against drug manufacturers contributing to the opioid addiction afflicting our nation.
Do I Have A Lawsuit will continue to monitor developments in this case.
Oxycontin is a painkiller opioid controlled release form of Oxycodone.
Other prescription drugs containing Oxycodone
Chills is a feeling of coldness occurring during a high fever, but sometimes is also a common symptom which occurs alone in specific people. It occurs during fever due to the release of cytokines and prostaglandins as part of the inflammatory response, which increases the set point for body temperature in the hypothalamus. The increased set point causes the body temperature to rise (pyrexia), but also makes the patient feel cold or chills until the new set point is reached. Shivering also occurs along with chills because the patient's body produces heat during muscle contraction in a physiological attempt to increase body temperature to the new set point. When it does not accompany a high fever, it is normally a light chill. Sometimes a chill of medium power and short duration may occur during a scare, especially in scares of fear, commonly interpreted like or confused by trembling. Severe chills with violent shivering are called rigors.
concurrent perspiration and chill usually associated with fear, pain, or shock
The term "acute mental confusion" is often used interchangeably with delirium in the International Statistical Classification of Diseases and Related Health Problems and the Medical Subject Headings publications to describe the pathology. These refer to the loss of orientation, or the ability to place oneself correctly in the world by time, location and personal identity. Mental confusion is sometimes accompanied by disordered consciousness (the loss of linear thinking) and memory loss (the ability to correctly recall previous events or learn new material.
Difficult and or labored breathing
Labored breathing is distinguished from shortness of breath or dyspnea, which is the sensation of respiratory distress rather than a physical presentation.
Still, many simply define dyspnea as difficulty in breathing without further specification, which may confuse it with e.g. labored breathing or tachypnea (rapid breathing). Labored breathing has occasionally been included in the definition of dyspnea as well. However, in the standard definition, these related signs may be present at the same time, but don't necessarily have to be. For instance, in respiratory arrest by a primary failure in respiratory muscles the patient, if conscious, may experience dyspnea, yet without having any labored breathing or tachypnea. The other way around, labored breathing or tachypnea can voluntarily be performed even when there is no dyspnea.
Lightheadedness is a common and typically unpleasant sensation of dizziness and/or a feeling that one may faint. The sensation of lightheadedness can be short-lived, prolonged, or, rarely, recurring. In addition to dizziness, the individual may feel as though his or her head is weightless. The individual may also feel as though the room is what causes the "spinning" or moving (vertigo) associated with lightheadedness. Most causes of lightheadedness are not serious and either cure themselves quickly or are easily treated.
Keeping a sense of balance requires the brain to process a variety of information received from the eyes, the nervous system, and the inner ears. If the brain is unable to process these signals, such as when the messages are contradictory, or if the sensory systems are improperly functioning, an individual may experience lightheadedness or dizziness.
Settlement Amount: $100 Million
Broken down As Follows:
Under terms reached with lawyers for the FTC, DeVry University must cancel any and all unpaid loans or balances owed by current and former students between the dates of September 1st 2008 and September 30th 2015.
Additionally, the lawsuit settlement forces DeVry to cancel over $20 million in debts owed to DeVry University by students for tuition, books, fees and other certain expenses.
DeVry University has been instructed to contact lawsuit beneficiaries via email within 30 days of the lawsuit settlement judgement being entered.
The FTC has made the following press release available to Do I Have A lawsuit and other true information or news providers for immediate release:
The results of an ongoing research study published to the American Journal of Epidemiology by widely respected doctors: Brian M. Lin, Sharon G. Curhan, Molin Wang, Roland Eavey, Konstantina M. Stankovic and Gary C. Curhan, submit that researchers have found links between certain over the counter drugs such as Aspirin, acetaminophen and nonsteroidal antiinflammatory drugs commonly known as NSAIDs and side effects directly associated with hearing loss in women.
The research was derived from data provided by nurses enrolled with the ongoing cohort study known as NHS I and NHS substudy Conservation of Hearing Study (CHEARS), which investigated factors associated with loss of hearing in participating female nurses.
Researchers focused on over the counter drugs known as aspirins such as Anacin by Insight Pharmaceuticals of Langhoren, Pennsylvania, Bufferin by Dr. Reddy's Laboratories Ltd. of Hyderabad, India, Midol by Bayer AG of Leverkusen, Germany, and Alka-Seltzer by Bayer AG of Leverkusen, Germany, Acetaminophen such as Tylenol by McNeil Consumer Healthcare, Fort Washington, Pennsylvania, and other antiinflammatory medications such as Ibuprofen, Naprosyn by Atnahs Pharma of London, United Kingdom, and Advil by Pfizer of Groton, Connecticut.
By researching hearing loss, reported by the nurses, and their use of these over the counter drugs, research doctors ascertained the link between hearing loss in women and regular use of Aspirins, NSAIDs and other over the counter non prescription drugs.
Based on evaluation, interpretation and investigation of this study, Do I Have A Lawsuit agrees with those findings by these research doctors as they are published, in stating that extended or longer use durations of Aspirin, NSAID and acetaminophen were correlated with higher risk of hearing loss in women of the study who used these over the counter drugs 2 or more times per week as indicated by study data.
Women who used these drugs less than 2 days per week did not indicate any increased risk of hearing loss.
While research continues, Do I Have A Lawsuit recommends our readers and community members consult their doctors and request specific information as it relates to you and loved ones about specific risks and benefits of any OTC or prescription drug.
Do I Have A Lawsuit will continue to monitor and research drug side effects and immediately notify our readers of any hearing loss lawsuit filed or initiated by our staff or affiliated attorneys
display black box warnings on all gadolinium-based imaging...
ProHance Side Effects Lawsuit
ProHance, brand name of Gadoteridol, is a popular gadolinium-based contrast agent manufactured by pharmaceuticals major Bracco Diagnostic. The contrast drug helps in improved MRI of the central nervous system. ProHance also helps radiologists easily distinguish leaky blood vessels and problematic tissues in patients during MRI scans. However, the side effects of the drug can lead to rare disorders, such as Nephrogenic Systemic Fibrosis and Nephrogenic Fibrosing Dermopathy, in people with impaired renal function. It has also been linked to liver problems, cardiovascular side effects, skin diseases, and other potentially life-threatening conditions.
ProHance and FDA Warnings
The FDA approved ProHance in 1999 for clinical use. Following numerous reports of epidermal and dermal side effects, the FDA issued a public health advisory in June 2006, informing health professionals about possible fatal skin disorders caused by the drug. A study by the Danish Health Authority in 2007 highlighted 25 Nephrogenic Systemic Fibrosis cases, where patients with impaired kidney and liver functions developed the rare disorder after taking gadolinium-based contrast injections during diagnostic tests.
The findings of the Danish report prompted the FDA to
Rare fungal meningitis caused by contaminated steroid injections has left 47 people sick and five dead in seven states. Preliminary investigations by the Centers for Disease Control and Prevention indicate that the outbreak is linked to steroid injections custom-made by New England Compounding Center, a Massachusetts-based specialty pharmacy. These epidural steroid shots used to alleviate back pain are suspected to have aspergillus fungus, a common mold considered the reason for the meningitis outbreak. FDA officials have discovered fungal infection in at least one sealed steroid vial at the production facility of the pharmacy in Framingham.
About 75 clinics in 23 states received 17,700 vials supplied by the pharmacy between July and September. A Nashville-based clinic is said to have received the largest consignment of steroid vials suspected to have been infected. The highest number of meningitis cases, 18 hospitalized and three deaths, has been reported from Tennessee. The Tennessee Department of Health confirmed the first meningitis case on September 21, 2012, following discovery of deadly brain infection in a patient, who had received methylprednisolone acetate spinal injection to alleviate back pain at an ambulatory surgery center. The CDC discovered another Tennessee man with a similar infection within a week. The list went up, with the increase in the number of meningitis cases reported in Tennessee, Michigan, Florida, North Carolina, Indiana, Virginia, and Maryland.
Federal and state health officials are also looking for other possible reasons leading to the present fungal meningitis outbreak, such as the solution and the anesthetic used during administration of these steroid injections.
On September 26, 2012, the compounding pharmacy issued a recall of three lots of possible contaminated methylprednisolone steroid injections while investigations over suspected contamination and pharmacy error were continuing. It expanded the recall on October 4 to include all its injectable drugs and vials of methylprednisolone acetate products supplied since July. The New England Compounding Center at Framingham, MA, is a specialty pharmacy authorized to create custom-made steroid injections. It mixes medications and drugs taking into consideration patient conditions, dosing requirements, specific allergies, and need to change medication. The FDA has advised consumers and healthcare professionals against using New England Compounding Center products until the investigation is over.
Methylprednisolone acetate is a corticosteroid used to deal with inflammation that causes back and spinal pain. The steroid is injected into the spine directly to contain inflammation and ease pain. Hundreds of people in the United States use these injections everyday to get relief from lower back pain caused by a herniated disk. According to a report by the Department of Health and Human Services' inspector general published in 2010, about one-third of 433 injections audited as samples failed to meet Medicare standards.
Tainted steroid causes fungal meningitis that leads to infection of the brain and spinal fluid. The infection starts with the spinal cord inflammation and gradually contaminates protective membranes surrounding the brain. Aspergillus-induced fungal meningitis is rare, and this condition can be fatal for those with weakened immune systems.
Meningitis signs, such as headache, neck stiffness, vomiting, fever, light sensitivity, and confusion, start within three to seven days of the infection and proceed to coma and death. The transmission occurs only through direct fluid contact. In case of contaminated steroids, it develops fast because of direct delivery to spinal canal. The treatment for fungal meningitis requires prolonged hospitalization from weeks to months.
According to a report by the Institute of Medicine of the National Academies, about 1.5 million U.S. residents die or face serious life threats due to medication or pharmacy error every year.
In June 2012, eight former patients sued the cardiac catheterization clinic of Exeter Hospital’s at New Hampshire for Hepatitis C exposure. The patients were diagnosed with Hepatitis C following their treatment at the hospital between October 2010 and May 2012. According to state health officials, 19 patients were infected with the disease after a hepatitis C infected employee of the hospital gave shots to patients with self-used needles. In February 2010, a Las Vega Endoscopy Center paid more than $3 million to settle 85 hospital infection lawsuits filed following similar outbreak of Hepatitis C in January 2008. In March 2012, reports of fungal eye infections led to recall of Brilliant Blue G dye used in eye surgery.
In March 2011, Birmingham-based compounding pharmacy Med IV recalled its Total Parenteral Nutrition products after investigating officials linked them to an outbreak of infection in six Alabama hospitals. The TPN was contaminated by Serratia marcescens bacteria that resulted in nine deaths. A number of wrongful death lawsuits have been filed against the compounding pharmacy by family members of deceased patients.
In August 2007, a Florida court awarded $33.3 million to family of a breast cancer patient, who died after being accidentally given a blood thinner dosage by technician at Walgreens Pharmacy. A superior court rejected Walgreens’ appeal challenging the judgment in the pharmacy error lawsuit and upheld the compensation awarded in March 2010.
In February 2009, Walmart Pharmacy paid an undisclosed sum to settle a wrongful death lawsuit filed by family of a Maryland man, who died in 2007. The pharmacy error lawsuit filed in a Baltimore court claimed that the 66-year-old died after he was given drugs prescribed for someone else. A similar case filed against Walmart in a Texas court in May 2010 is awaiting trial.
A pharmacy error lawsuit has also been filed against Detroit-based Rite-Aid Pharmacy following death of a man caused by wrong medication in 2007. According to the lawsuit filed in Michigan’s Wayne County Circuit Court in December 2009, 54-year-old John Sheridan died because of Temodar overdose. The technician at the pharmacy gave the cancer treatment drug that was 10 times more potent than the prescribed dose.
metallosis have been associated with it.
Following the DePuy ASR recall, there have been numerous complaints that DePuy Pinnacle hip implant is causing similar problems when used with a metal liner. Patients and doctors demand that, with more than 1,300 adverse event reports filed with the FDA against Pinnacle hip implant, it is high time DePuy Orthopedics issued a recall for the device, which is reported to have a 13 percent failure rate. The device is linked to potential side effects, including severe pain, hip dislocation, hip replacement failure, metal toxicity, and need for a revision surgery in many cases.
The FDA approved the DePuy Pinnacle® Ultamet® metal acetabular inserts in 2001. However, not all Pinnacle hip devices are metal on metal, but the metal bearing surface poses the risk of revision compared to other bearing surfaces, including plastic, polyethylene, ceramic, and polymer. The Pinnacle metal on metal hip replacement system with a femoral head, particularly the one that is more than 32 mm, poses a threat of revision surgery. Though the Pinnacle Ultamet does not have as high a failure rate as ASR implants, a large number of incidences of
metal poisoning or metallosis. In some patients, it...
In 2008, Zimmer Holdings suspended sale of Durom Acetabular Cup following numerous complaints of a high implant failure rate. Since 2006, when Durom Cup came to be used in the United States, numerous complaints and lawsuits have been filed against Zimemr Holdings. Most of the lawsuits filed against Zimmer allege that the defendant did not disclose the risks associated with the hip implant cup when it marketed the product. However, Zimmer continues to deny the allegations, precisely blaming the surgeons for the high hip implant failure rate. Many patients have complained that the Durom Cup failed within two years of implantation, as a result of which, they had to bear severe pain and undergo a revision surgery.
Patients complain of pain and stiffness following their hip replacement surgery with Durom Cup. They allege that they experience so much stiffness and sharp pain in the groin that they cannot walk properly. Most of the patients also allege that they even find it difficult to come down the stairs.
The Durom Cup had been implanted in more than 12,000 patients in the country from 2006 to 2008. According to reports, about 11 percent of the Durom Cup implants failed in the first two years. However, Zimmer claims that the product can last for 15 years, saying that the metal hip replacement system is far more durable than traditional implants.
In fact, the Durom Cup is a metal-on-metal hip replacement system, with multiple metal components designed to fit into a “ball and socket” formation. As the ball rotates and rubs against the cup-like socket, it sometimes presses against the edge of the cup, thus generating a large volume of microscopic metal shavings into the patient’s bloodstream. The metallic debris can be absorbed by the soft tissue, resulting in
cognitive capabilities, and confusion.
DePuy Orthopedics has issued a recall for two of its hip replacement systems following reports indicating a higher-than-normal implant failure rate. DePuy recall came after more than expected number of people had to undergo secondary surgery due to hip implant failure. Since their approval in 2003, DePuy ASR hip implants have been used in over 93,000 hip replacement surgeries. Hip implants generally last 15 years; however, many patients have complained that their artificial hips lasted only two or three years, following which they were required to undergo expensive and painful revision surgeries, which caused them more pain and loss of money.
The FDA has received over 300 complaints against DePuy Orthopedics regarding defective hips. Complaints against DePuy started surfacing in 2009; however, DePuy issued a recall only after a long wait of about 18 months, after its defective product had caused more harm to many other patients throughout the country.
DePuy has recalled both products because of their high failure rate.DePuy’s metal-on-metal hip products use a metal ball and metal cup, which are installed in the place of the natural ball and socket hip. When DePuy launched its new metal-on-metal hips, it claimed that the product was stealthier than traditional hips made of metal and plastic. However, it ignored the risk of metal toxicity posed by metal-on-metal hip products. Even a number of complaints registered against DePuy claim that the metal-on-metal hip implants caused metal toxicity in many patients.
Analysts believe that when metal ions rub against each other as a result of friction and movement, these metal particles spread into the surrounding tissue and bloodstream. Further, these metal ions do not allow the cup to bond properly with the bone, causing cup loosening and hip fracture, besides other complications, including persistent pain, inflammation, discomfort, lethargy, dizziness, headache, gastrointestinal problems, food allergies, muscle and tissue damage, bone fractures, and Pseudotumors.
Metal toxicity causes heart problems, skin rashes, nerve damage, depression, numbness, loss of sensory and
A research report published in May...
Provera, manufactured by Upjohn Pharmaceuticals, a unit of Pfizer, has been linked to breast and uterine cancer, blood clot disorder, and a number of other side effects. The drug made up of medroxyprogesterone acetate is used to treat menopausal symptoms, abnormal menstrual cycle changes in females, irregular menstrual, uterine bleeding, and premenstrual tension. It regulates secretion of progesterone, a female sex hormone regulating ovulation and menstrual periods. The drug also prevents overgrowth of the uterine lining caused by estrogen replacement therapy.
A major study the National Institute of Health conducted in 2002 linked Provera and similar hormone drugs to a significant increase in the risk of cardiovascular problems, blood clots, and breast cancer. The study advised patients having epilepsy, migraines, seizures, asthma, heart problems, and diabetes to avoid the medication or consult the doctor. According to another research by Women's Health Initiative Memory Study, elderly postmenopausal women treated simultaneously with the drug and the estrogen therapy are more likely to develop dementia.
The FDA has categorized Provera under the pregnancy category D. The drug can cause minor birth defects in children if expectant mothers are administered the drug. There have been reports linking the drug to genital abnormalities in babies born from mothers who took the drug during the first trimester of pregnancy. Male babies born from such mothers are likely to suffer from hypospadias, a condition in which the penis opens underside than the tip. Clitoris enlargement and labia fusion are the foremost problems the female fetus is likely to have due to the drug side effects.
Terumo Cardiovascular Systems Urgent, Nationwide Worldwide Recall of Pediatric Arterial Cannulae
Terumo Cardiovascular Systems (Terumo CVS) are manufacturers of products that are required for specialized needs of the cardiac surgical teams for cardiopulmonary bypass and intra-operative monitoring. They develop and introduce new cannulae to address the needs of cardiac surgeons and are a trusted brand by many. One of their latest products is the Tenderflow Pediatric Arterial Cannulae that is required during heart bypass surgery. Injury from this product may result in a lawsuit by an attorney if lawyers can prove fault with the manufacturer.
What is a cannula?
A cannula is used by cardiac surgeons during cardiac bypass surgeries. It is a disposable tube that is inserted into the aorta during the procedure. The purpose is to perfuse the ascending aorta. Another equipment needed during the procedure is the ‘introducer’. The introducer is needed for smooth progress during insertion of the cannula and to stabilize the device. The introducer is subsequently removed. If the doctor experiences any difficulty in drawing back the cannula then it has to be removed and replaced. However, the risk involved here is that of aortic damage or blood loss which may sometimes be fatal.
What are the risk involved and why the recall has been necessitated?
Terumo Pediatric Arterial Cannulae were distributed to 68 hospitals throughout United States. It was also distributed to distribution centers in Australia, Canada and Europe. The company had received reports from at least five doctors regarding difficulty in it usage. The risk involved is a cause of concern. If they are unable to retract the introducer smoothly then it may cause serious injury to some of their patients which may turn out to be life threatening and result in permanent injury lawsuits, as well as wrongful death lawsuits filed by surviving family members.
In an effort to avoid any attorney investigations , the company decided to voluntarily recall its Tenderflow Pediatric Arterial Cannulae from the 21 lot codes that had been sent to the hospitals. A letter informing the hospitals had been sent on October 16, 2008. The company also notified them not to use the product unless it is medically necessary. Moreover, the company has recommended them to use the cannula without the introducer in situations where it is extremely necessary to do so.
The company has also informed the US Food and Drug Administration about the recall. A firm press release to this effect has been released by the FDA dated December 01, 2008. Customers should contact an attorney for injury lawsuit information release.
Please submit your case information for all Zimmer Durom Lawsuit...
Please submit your case information for all Zimmer Durom Lawsuit questions.
Premises Liability Lawsuit The Meaning and Principles
Premises Liability Lawsuit Do I Have A Lawsuit
Philadelphia resident Louis Holland filed a premises liability lawsuit against Amtrak on June 12, 2013, holding it responsible for injuries received at a property owned by the railroad passenger transport corporation. The plaintiff slipped and fell on greasy substance on the escalator he was riding and suffered teeth fracture and multiple face injuries. According to the premises liability lawsuit, the plaintiff has demanded $50,000 in compensation with interest and legal costs, citing that the railroad corporation had failed to keep away dangerous and defective conditions on its property. In 2005, a similar premises liability lawsuit ended with $2.5 million settlement offer from the Philadelphia Fresh Food Terminal that operates the Regional Produce Market.
Premises liability lawsuit constitute 22 percent of all tort litigations filed in the United States. Second only to automobile torts, the plaintiffs filing such lawsuit are from a wide category, including visitors, tourists, employees, and students, while defendants range from individuals and municipal agencies to corporate, public, and private bodies, shops, and restaurants. In the last week of June 2013, Boy Scouts of America and Lewis and Clark Council Inc. paid an undisclosed sum, presumed to be more than $60,000, to a 51-year-old assistant scout master, who lost his leg after being crushed under a fallen tree in 2010.
A similar premise liability lawsuit has been filed by a West Virginia man against the Hardee’s of Man on June 18 claiming compensation for injuries he had following breakdown of chair while having his food at the restaurant. A Tuscan nightclub is facing a premises liability lawsuit for falling to provide security for its customers. Firing by a gun wielding customer in the club led to death of a man. The families of six children, who died in a fire at a Chicago apartment, were awarded $6 million in damages.
toxic exposure, car accidents, defective products, slip...
A personal injury lawsuit is a legal action that empowers one to seek compensation for damages, physical injuries, emotional distress, and loss of job caused by another. It addresses a civil wrong where negligence or deliberate malice on the part of one individual results in pain and suffering to another. According to the law, the victim has legal rights to sue the offender, who failed to ensure reasonable care, to recover losses caused by injury or harm to property.
Personal injury comes under the tort law designed to protect individuals from injuries or losses caused by willful act or negligence of another individual, organization, or even the state. The main purpose of the law is to send a strong message to the offender that they are liable for the harm caused to another and discourage them from committing the similar offense. A personal injury lawsuit entitles one to sue another individual or organization for pain and suffering, emotional distress, loss of earning capacity, companionship, and amenities, financial losses incurred, medical and legal expenses, and even expected future losses.
The spectrum of personal injury law is quite wide and includes a range of injuries and accidents, including
A 2007 Southampton study showed...
The question whether food dyes are linked to hyperactivity disorder in children has been lingering for a few decades now. The Food and Drug Administration was so far rejecting the issue; however, now it has agreed to go ahead with a review on the possible causative link between food dyes and hypersensitivity in kids or irritability, insomnia, and such some nonspecific behaviors. Its review panel held a two-day convention on the issue in response to a petition filed in 2008 by the Center for Science in the Public Interest seeking a ban on Red 40, Yellow 5, and six other dyes, saying that the dyes exist in food only to “trick consumers.” At the end of the two-day meeting, the advisory panel has recommended the agency to further conduct an assessment study to understand the causative link between food coloring and hyperactivity in kids, though ruling out the need for addition of package warnings for products containing dyes.
Scientists, doctors, researchers, and consumer representatives comprising the FDA review committee narrowly voted 8-6 against the demand for label warnings on food packages. However, the committee suggested that packages should list food colorings without putting any kind of warning label. The committee affirmed that there is lack of evidence to prove any kind of causative link between certain food dyes and attention deficit disorder in children. However, the panel agreed that foods eliminating dyes appear to work in the case of some children with behavior problems. The advisory committee agreed that hyperactivity and some behavioral problems may be aggravated by food dyes in "certain susceptible children."
The 14-member panel voted 13-1 against the proposal that doctors should recommend food-dye-free diets to parents of children with ADHD (attention deficit hyperactivity disorder); rather, it suggested that parents who think trying such diets might be helpful to their children should be supported. Citing lack of definitive information about the direct link between food dyes and attention deficit hyperactivity disorder, the panel called for more research into the relation between food coloring and childhood hyperactivity by the National Institutes of Health.
Now the FDA will review the committee’s recommendations to decide further action. It remains unclear how many kids fall under the class of “certain susceptible children” and whether the FDA would continue to ignore such kids, who are exceptions to a major section of children unaffected by artificial dyes. Public health advocates believe that though dyes are not directly the underlying cause of hyperactivity, these do affect some children, which is enough of a cause to ban the additives.
Disappointed at the meeting’s conclusion, Michael Jacobson, the director of Center for Science in the Public Interest, criticized the panel for looking for “perfect scientific evidence” of the link between artificial dyes and colors and hyperactivity in kids. However, he said he was happy to note that the FDA gave recognition to the fact that it is a serious issue and accepted to conduct a review panel. Jacobson seeks warnings on food package labels so that parents can decide whether they would opt for buying that particular product for their kids knowing their possible side effects.
Parents who testified at the hearing affirmed that there is a causative link between food dyes and their kids’ behavior. They even brought along improved report cards of their kids, which affirmed that they had improved considerably after food dyes had been eliminated from their diet, saying that their decision to discontinue use of dyes had proved to be “life changing” for their kids. They urged the panel to recommend warning labels on food products so that parents know there might be a problem.
Consumer groups now ask how many more years does the FDA need in order to secure the required data on accurate numbers of kids affected by hypersensitivity, linked to food dyes. They argue that it is wrong to continue risking public health when some kind of link exists between food coloring and hyperactivity for some kids.
Emergency lights and sirens are installed in all police cruisers...
A personal injury lawsuit has been filed on behalf of the Houston Texas family of Dr. Estella Medrano whom passed away as a result of injuries sustained during an August 30th 2010 auto crash accident with 27 year old Houston police officer Kyle Dozier.
The speeding Houston police car was allegedly responding to an emergency call when the officer failed to activate his cruisers warning lights and sirens while driving up to 90 miles per hour in darkness within a 35 mile per hour zone.
Amiodarone Side Effects
Amiodarone HCI injection in D5W is...
The Amiodarone HCI injection is for intravenous use only and
contains amiodarone HCI. Amiodarone is a class 3 antiarrhthmic drug.
The Amiodarone HCI injection is used in patients noncompliant
with other therapy for the initiation of treatment and prophylaxis of
ventricular fibrillation recurring frequantly and hemodynamically unstable
The starting dose of Amiodarone that is recommended is about
1000mg over the span of the first 24 hours. The first dosing is broken down
into 150mg over the first 10 minutes followed by 360 mg injected slowly over
the proceeding 6 hours followed by the remaining 540mg over the remaining 18
hours. After the first 24 hours the infusion rate should be maintained at
0.5mg per minute (720mg per hour).
This fight will be a...
Judicial proceedings in the litigation of DePuy ASR hip replacement recall lawsuits will be heard in the Northern District of Ohio / Toledo Ohio. The DePuy hip implant lawsuits have been assigned MDL or Multi District Litigation number MDL 2197.
If you have already submitted your case or called the lead attorney handling these cases for Do I Have A Lawsuit then your claim will automatically be registered and no further action is required by you.
If you have not recieved your packet or have not yet submitted your DePuy ASR hip replacement implant lawsuit via the contact form, you can still submit your case by filling outthe short form found hereor calling the lead firm directly for immediate help, registration and information.
DePuy ASR hip replacement implants have been recalled globally due to hip implant failure and metal toxicity poisoning found to cause tissue death along with other potentially life threating injuries to implant patients.
Every single recalled Depuy hip implant patient has been instructed to seek medical attention in the form of test for metal toxins within their body. You may have recieved a letter from your orthopedic surgeon detailing the hip implant recall and or recieved a telephone call from Johnson and Johnson instructing you to seek revision surgery and pay for the surgery yourself.
We are completely appalled by this and feel that not only should Johnson and Johnson Depuy pay for any revision surgery upfront, they must pay for damages as well.
Our team of associated attorneys are no longer accepting new...
In August 2009, five people sued...